Bio-Rad Laboratories Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -17.1% | -13.9% | +39.9% | +67.6% | -24.1% | +4.6% | -10.3% | +3.8% | +36.4% | -34.4% | -8.7% | – | |
| – | -0.3% | -0.3% | -1.9% | +6.9% | +26.7% | -22.7% | -200.0% | – | -3.8% | -3.8% | +0.5% | – | |
| – | +1.9% | -5.6% | -2.0% | +4.0% | +5.1% | -6.7% | -200.0% | – | +6.7% | -5.7% | -3.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -1,358.3% | – | -74.2% | -23.4% | -200.0% | – | – | -166.3% | – | – | |
| – | -4.1% | -4.9% | +5.2% | +50.5% | -32.6% | -19.8% | +32.8% | -30.6% | +44.5% | -34.5% | +6.7% | – | |
| – | – | -159.7% | -28.2% | +79.9% | -45.1% | – | -4,079.3% | -62.7% | -20.5% | +172.5% | -28.4% | – | |
| – | +1,838,484.0% | -100.0% | – | – | – | – | – | +28.2% | – | – | -52.9% | – | |
| – | +838.0% | -97.6% | +2,026.8% | -3.1% | -100.0% | +727,757.1% | +37.6% | -61.9% | +423.8% | -82.9% | -34.1% | – | |
| – | – | – | – | – | -59.0% | +143.9% | +100.0% | -100.0% | – | -50.0% | +100.0% | – | |
| – | +654.3% | – | -460,038.1% | -0.6% | -72.7% | +272.2% | +39.5% | -61.5% | – | -1,433.3% | -36.6% | – | |
| – | -179.5% | – | -188.6% | – | +1,635.1% | -57.1% | -554.7% | – | +398.1% | -117.6% | – | – | |
| – | -27.7% | -23.7% | +86.9% | +80.6% | -18.7% | +17.5% | -25.9% | +26.0% | +33.5% | -34.4% | -14.6% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.